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Abstract
Background: To facilitate the experimental search for novel maternal serum biomarkers in prenatal Down Syndrome
screening, we aimed to create a set of candidate biomarkers using a data mining approach.
Methodology/Principal Findings: Because current screening markers are derived from either fetal liver or placental
trophoblasts, we reasoned that new biomarkers can primarily be found to be derived from these two tissues. By applying a
three-stage filtering strategy on publicly available data from different sources, we identified 49 potential blood-detectable
protein biomarkers. Our set contains three biomarkers that are currently widely used in either first- or second-trimester
screening (AFP, PAPP-A and fb-hCG), as well as ten other proteins that are or have been examined as prenatal serum
markers. This supports the effectiveness of our strategy and indicates the set contains other markers potentially applicable
for screening.
Conclusions/Significance: We anticipate the set will help support further experimental studies for the identification of new
Down Syndrome screening markers in maternal blood.
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Introduction
For over two decades, prenatal screening for Down Syndrome
(DS) has been available to pregnant women. A screening
procedure usually consists of a risk calculation based on maternal
serum measurements and other parameters like nuchal translu-
cency and maternal age, after which women with a high predicted
risk can opt for invasive testing such as amniocentesis or chorion
villus sampling. Initially, the most commonly used method for risk
calculation was the second trimester triple test, which combines
serum levels for alpha-fetoprotein (AFP), unconjugated estriol
(uE3), and the free b subunit of human chorion gonadotrophin (fb-
hCG) with maternal age [1,2]. In recent years, this test has been
largely replaced by the first trimester combined test, which is based
on fb-hCG and pregnancy-associated plasma protein A (PAPP-A)
serum concentrations, ultrasound nuchal translucency (NT)
measurements and maternal age [3]. The latter test is the method
currently available to pregnant women in the Netherlands.
Despite international experimental effort to improve the DS
screening, both the Detection Rate (DR) and False Positive Rate
(FPR) can still significantly be improved upon. In the Netherlands,
the current DS screening has a DR of 75.9% and an FPR of 3.3%
[4]. Most research effort in this field is focused on finding new
biomarkers for which serum levels can be added to the risk
calculation algorithm. In recent years, proteomics methods for
large-scale protein quantitation have been employed to facilitate
the search for such biomarkers [5–10]. However, the performance
of candidate biomarkers obtained by such studies are not always
reproducible, and also established DS pregnancy biomarkers are
not always successfully confirmed in such studies, likely due to
issues related to technical sensitivity and reproducibility.
A recent study by our group used bead-based multiplexed
immunoassays to test 90 different analytes in first trimester
maternal serum samples for DS pregnancies and controls [7]. This
study identified seven new potential biomarkers that allow for a
more accurate first trimester risk prediction, while confirming the
long-known usefulness of PAPP-A. The set of 90 analytes was not
pregnancy- or DS- specific but based on a pre-fixed commercially
available set. We reasoned that with a set that is more focused on
markers relevant for pregnancy or DS, more and also more
specific biomarkers can be found. Hence, we set out to develop
such a set by analysis and integration of publicly available data.
The amount of information on genes and proteins in databases
is increasing rapidly, which allows for a bioinformatics approach
that involves automated collecting and combining information
from biological databases, known as data mining. Recent studies
using data mining for identification of blood based cancer
biomarkers showed the successfulness of this approach [11,12].
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8010Current DS screening protein biomarkers can be traced to
originate from two tissues, namely fetal liver (e.g. AFP) and the
placenta (e.g. fb-hCG, PAPP-A). The non-protein serum bio-
marker uE3, routinely used in 2
nd trimester screening, is produced
by the placenta from its precursor dehydroepiandrosterone sulfate
derived from the fetal adrenal glands and liver [13,14]. Placental
markers can be assigned more specifically to the trophoblast cells,
which are involved in both the implantation of the embryo into the
endometrium as well as the production of hormones required for
establishing and sustaining pregnancy. Indeed, abnormal tropho-
blast differentiation has been observed in placentas of DS
pregnancies [15,16]. As the current screening biomarkers are all
derived from the two tissues mentioned (i.e. fetal liver and
placental trophoblast cells), we hypothesized that several novel
useful biomarkers can primarily be found to be derived from these
two tissues. To identify such protein biomarkers we combined data
from several publicly available sources.
Methods
Analysis of Tissue-Specific Gene Expression Data
Human tissue-specific gene expression data were analyzed using
the Symatlas web-interface (http://symatlas.gnf.org) based on data
previously published by Su et al [17,18]. Symatlas data were
considered most useful for this study as it provides the largest
publicly accessible data collection on multiple tissues, including
both adult and fetal tissues. Tissue data used were both from the
Human GeneAtlas GNF1H (gcRMA-normalised) (79 tissues) and
the Human GeneAtlas U95A (44 tissues). Using the web-interface,
these data sets were queried for the number of genes highly
expressed in fetal liver or placenta, according to different
stringency levels. Such a stringency level consists of a minimal
ratio for the gene expression in a target tissue (in our case placenta
or fetal liver) compared to the median expression of that gene
across all tissues examined. Using various stringency levels, the
number of tissue-specific genes obtained for each stringency level
was determined for fetal liver as well as placenta. The resulting
data were imported into the statistical program R (www.r-project.
org) [19] and the data distribution was assessed to determine the
nonspecific underlying trend over lower stringency levels. This
revealed that for lower thresholds this trend could be approxi-
mated with a power law distribution, where a two-fold increase in
the threshold led to a four-fold decrease in the number of genes
expressed above that threshold. We refer to this trend as the
nonspecific underlying trend. For higher stringencies, the number
of genes began to decrease at a slower rate, indicating an
enrichment for tissue-specific genes over the nonspecific trend.
Based on this finding, a threshold was set that yielded
approximately 10 times more tissue-specific genes than could be
estimated based on the nonspecific underlying trend. In other
words, using the trend for nonspecific genes at lower stringency
levels, a stringency threshold was chosen that was high enough to
consider 90% of the genes highly expressed in either fetal liver or
placenta to be specifically derived from that tissue and not be a
statistical artefact. These genes were used in subsequent analysis
steps. The same approach was used to enrich fetal-liver-specific
genes compared to adult liver-specific genes.
Text-Mining
As text-mining is still a developing field, we wanted to include
more than one text-mining tool to restrict the chance of false
negatives. For that reason two applications were combined as they
use different approaches to search partially different databases,
and therefore can be considered complementary. The first of these
is Anni (http://www.biosemantics.org/anni/) [20], which pro-
vides an ontology- and thesaurus-based interface to Medline and
retrieves associations for several classes of biomedical concepts
(e.g. genes, drugs, and diseases). These concepts are given a
concept weight, which indicates their relevance to the applied
search term. The second application is Polysearch (http://wishart.
biology.ualberta.ca/polysearch) [21], which supports different
classes of information retrieval queries against several different
types of text, scientific abstract or bioinformatic databases such as
PubMed, OMIM, DrugBank, SwissProt, the Human Metabolome
Database (HMDB), the Human Protein Reference Database
(HPRD), and the Genetic Association Database (GAD). The
relevancy scores of the obtained genes or proteins are expressed as
Z scores, i.e. as standard deviations above the mean. The two
applications were searched for genes associated with the terms
‘‘trophoblast’’, ‘‘cytotrophoblast’’, and ‘‘syncytiotrophoblast’’.
Significance criteria for Anni were based on a minimally tenfold
enrichment over the statistically determined distribution of the
concept weight. For PolySearch, a Gaussian distribution was used,
based on the software documentation. Gene lists obtained for the
three terms were combined and subsequently manually adjusted to
resolve ambiguous or redundant gene symbols.
Assessing Applicability for Blood-Based Detection
To determine if putative biomarkersi d e n t i f i e db yg e n ee x p r e s s i o n
analyses and/or text mining are potentially blood-detectable, they
were cross-checked against two different data resources. Proteins
were considered blood-detectable if they had at least one of the Gene
Ontology (GO) annotation terms ‘‘extracellular region’’, ‘‘extracel-
lularregionpart’’,or‘‘extracellularspace’’;oriftheywereincluded in
the Human Plasma Proteome (HPP) list. GO (http://www.
geneontology.org) [22] annotations are partially based on computa-
tional predictions whereas the HPP list [23] is based on a
combination of experimental methodologies. The latter approach
revealed some blood-detectable proteins not predicted by Gene
Ontology, but lacked some low-abundance proteins including protein
hormones [23]. As with the text-mining tools, these approaches were
therefore considered complementary and results were combined.
Results
Identification of Tissue-Specific Candidate Genes
The DS screening biomarkers currently implemented in the first
trimester combined test or the second trimestertripletest arederived
from two tissues, namely fetal liver and placental trophoblasts.
Therefore, the first step in our data mining approach consisted of
identifying genes specifically expressed in either one of these two
tissues (see Fig. 1 for an overview of the various selective steps).
The tissue-related gene expression resource Symatlas was
searched for genes expressed in either fetal liver or placenta, at
a level that is a (user-definable) multiple of the median expression
for that gene across all tissues. By using various threshold levels
and statistical analysis, we found that at a gene expression
threshold of 30 times the median tissue expression, ten times more
genes were identified by the Symatlas query than were expected
based on the nonspecific trend. This applied to fetal liver as well as
placenta. Therefore, we used this criterion to select genes that have
a high probability of being specific for these individual tissues. This
approach resulted in 158 proteins specific for fetal liver and 229
for placenta, respectively (Fig. 1).
Applying Additional Relevance Criteria
The second step consisted of further prioritizing our set of genes
by ensuring that the genes selected in step 1 are not only highly
Novel Down Syndrome Biomarkers
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mentioned. In the case of fetal liver-specific genes, we again used
Symatlas to ensure that the expression in fetal liver exceeded at
least ten times that of adult liver, thus narrowing down the list
from 158 to 51 genes (Fig. 1). For placenta-specific genes we used
two complementary textmining tools (Anni and Polysearch) to
select genes related to three trophoblast-related search terms
(trophoblast, cytotrophoblast, syncytiotrophoblast). For Anni,
genes with a concept weight .0.0001 (based on yielding ten
times more terms than expected for a nonspecific distribution) and
for Polysearch genes with a Z value.1.6 for at least one of the
terms were selected. This way, 181 genes were found, 50 of which
were also found to overlap with the previous selection of 229
placenta-specific genes (Fig. 1). We applied a different filtering
method for the two tissues because Symatlas does not include gene
expression data specific to trophoblasts or its two subtypes,
whereas text mining was less able to make a distinction between
proteins related to fetal or adult liver.
The 51 fetal liver-specific genes, and 50 trophoblast-related
genes were subsequently analyzed for detectability in blood.
Selection of Blood-Detectable Markers
For implementation of a biomarker in a routine human
screening program, it is essential that it can be detected in serum
or plasma. For the markers selected by the previous steps, we
examined which ones had a Gene Ontology annotation as being
extracellular, or were part of the experimentally derived Human
Plasma Proteome list compiled by Anderson et al. [23]. This final
selection step resulted in 49 individual blood-detectable markers
(Fig. 1, Table 1). For fetal liver and placenta, these numbers were
19 and 31, respectively, with IGF2 being part of both sets (Fig. 1,
Table 1).
Discussion
The aim of this study was to design a set of new potential blood-
detectable biomarkers for prenatal DS screening by computational
data mining, that is more focused on DS screening than currently
available commercial multiplex kits or high-throughput methods
for whole proteome analysis. By combining data from different
(publicly available) data sources into a three-stage approach
(summarized in Fig. 1), we identified 49 of such protein markers
(Table 1). Our combined list contains three biomarkers that are
currently widely used in either first- or second-trimester DS
screening, namely AFP, PAPP-A and fb-hCG. This demonstrates
that the method used is able to identify relevant DS screening
biomarkers. In addition, the list contains several other proteins
which have been examined for their potential as DS screening
biomarkers by several research groups, such as the inhibin chains
INHA and INHBA [24–27], the (protein-identical) placental
lactogen genes CSH1 and CSH2 [28], placental growth hormone
(GH2) [29–31], placental growth factor (PGF) [32], IGFBP1 [30],
or PP13 (LGALS13) [33]. For five of these proteins (INHA,
CSH1, CSH2, GH2, PGF), significant differences in concentration
exist between DS and euploid pregnancies, and therefore these
can be used as a biomarker in DS screening. Additionally, two
collagen-related markers, COL1A1 and COL3A1, (as well as
IGFBP1) have been described to have different amniotic fluid
levels in DS pregnancies [10] and it is conceivable that this also
applies to the corresponding maternal serum levels although this
remains to be established.
While identifying AFP, PAPP-A as well as fb-hCG as DS
screening biomarkers, our approach failed to identify the second
trimester biomarker unconjugated estriol (uE3). However, as uE3
is not a protein biomarker, it is not supported by our strategy
based on gene expression and protein data integration. Another
biomarker that our approach failed to detect but has been
described in the literature is ADAM12. This protein is both highly
expressed in placenta and extracellular, but failed the criteria used
in the textmining step. It should be noted, however, that most
recent studies find this biomarker to be informative only before 10
weeks of gestation, so the applicability of this protein is already
limited [34–38]. The finding that two complementary textmining
methods did not find sufficient evidence for association of
ADAM12 with trophoblasts can either indicate that current
literature databases only provide weak evidence for this associa-
tion, or that both textmining tools were not successful in detecting
an existing association. As textmining is a developing field, both
options are plausible. A recommendation for future studies of this
kind might therefore be to consider including further textmining
tools based on additional search algorithms.
Among the 49 proteins in Table 1, several overrepresentations
of biological processes can be observed. Among the fetal liver-
derived genes the five collagen genes are most apparent, but there
are also a number of proteins related to innate immunity such as
C5, PF4, PPBP, S100A8, and S100A9. These immunological
proteins can be ascribed to the central role the fetal liver has in
fetal hematopoiesis. For the placental trophoblast-derived proteins
Figure 1. Schematic representation of the steps employed in
our data mining strategy and the number of genes selected
after each step.
doi:10.1371/journal.pone.0008010.g001
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Symbol Chrom Description (synonym) Potential
Fetal liver-derived markers
AFP 4 alpha-fetoprotein In use
ANGPTL3 1 angiopoietin-like 3
C5 9 complement component 5
COL1A1 17 collagen, type I, alpha 1 Indications
COL1A2 7 collagen, type I, alpha 2
COL2A1 12 collagen, type II, alpha 1
COL3A1 2 collagen, type III, alpha 1 Indications
COL5A2 2 collagen, type V, alpha 2
DEFA3 8 defensin, alpha 1
DLK1 14 delta-like 1 homolog
ELA2 19 elastase 2, neutrophil
GPC3 X glypican 3
IGF2 11 insulin-like growth factor 2 (somatomedin A)
PF4 4 platelet factor 4 (CXCL4)
PPBP 4 pro-platelet basic protein (CXCL7)
RRM2 2 ribonucleotide reductase M2 polypeptide
S100A8 1 S100 calcium binding protein A8 (calgranulin A)
S100A9 1 S100 calcium binding protein A9 (calgranulin B)
SPTA1 1 spectrin, alpha, erythrocytic 1
Placental trophoblast-derived markers
ADM 11 adrenomedullin
ALPP 2 alkaline phosphatase, placental
CDH1 16 cadherin 1, type 1, E-cadherin
CDH11 16 cadherin 11, type 2, OB-cadherin
CGA 6 glycoprotein hormones, alpha polypeptide
CGB5 19 chorionic gonadotropin, beta polypeptide (bHCG)I n u s e
CRH 8 corticotropin releasing hormone
CSH1 17 chorionic somatomammotropin hormone 1 (placental lactogen) Biomarker
CSH2 17 chorionic somatomammotropin hormone 2 Biomarker
EBI3 19 epstein-barr virus induced gene 3
EGFR 7 epidermal growth factor receptor
FN1 2 fibronectin 1
GH1 17 growth hormone 1
GH2 17 growth hormone 2, placenta-specific growth hormone Biomarker
IGF2 11 insulin-like growth factor 2 (somatomedin A)
IGFBP1 7 insulin-like growth factor binding protein 1 Examined
INHA 2 inhibin, alpha Biomarker
INHBA 7 inhibin, beta A (activin A, activin AB alpha polypeptide) Examined
INSL4 9 insulin-like 4
LGALS13 19 lectin, galactoside-binding, soluble, 13 (PP13) Examined
PAPPA 9 pregnancy-associated plasma protein A, pappalysin 1 In use
PGF 14 placental growth factor Biomarker
PLAC1 X placenta-specific 1
PLAU 10 plasminogen activator, urokinase
PRL 6 Prolactin
PSG5 19 pregnancy specific beta-1-glycoprotein 5
SERPINB2 18 serpin peptidase inhibitor, clade B, member 2
SERPINE1 7 serpin peptidase inhibitor, clade E, member 1 (PAI1)
SPP1 4 secreted phosphoprotein 1 (osteopontin)
Novel Down Syndrome Biomarkers
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four proteins (PLAU, SERPINB2, SERPINE1, TIMP3) are
involved in tissue remodeling. Both these processes are associated
with the role of placental trophoblasts in the production of
hormones required for establishing and sustaining pregnancy as
well as the implantation of the embryo into the endometrium.
Given that most of the identified markers are associated with a
small number of biological processes, it becomes likely that these
pathways might also harbor other potential DS screening markers
that do not meet the criteria used in our approach or for which
insufficient data are available.
As Down syndrome is caused by a (partial)trisomy of chromosome
21, it seems counterintuitive that none of the markers in Table 1 are
located on chromosome 21. Although it might be expected that genes
on this chromosome are expressed at an approximately 1.5-fold
higher level compared to other genes and could therefore act as
suitable biomarkers, this assumption does not fully hold in
comparative studies [39–41]. Furthermore, proteomic studies
including our own found no increased presence of chromosome 21
proteins among the differentially expressed proteins [5–10]. More-
over, although partial trisomy 21 is sufficient for DS, efforts to
associate DS with a smaller chromosomal region have excluded the
possibility of a single region being responsible for all aspects of the
phenotype [42–45]. Additionally, several characteristics of a DS
phenotype are also found for other types of aneuploidy, indicating
that the higher expression of genes located on chromosome 21 is only
linked indirectly to DS phenotype and mainly acts through
disregulation of genes on other chromosomes. This can also explain
why current DS screening biomarkers are not located on
chromosome 21 and the pregnancy screening biomarkers in use
are also predictive for other chromosomal aberrations such as
Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13).
This actually creates the possibility that some of the markers
mentioned in Table 1 are not only applicable to DS screening, but
also to pregnancies with other types of fetal aneuploidy.
By means of integrative data mining we have derived a set of
candidate Down Syndrome screening biomarkers. As the first two
filtering steps are both based on a minimally ten-fold enrichment
or induction over the corresponding background, we expect the
number of false positives, i.e. not relevant markers, to be low. This
is corroborated by the presence of eight proteins in our set that are
in use or can be used as biomarker for DS screening and five other
proteins for which this has been studied. However, before
biomarkers can be tested in a large-scale cohort study, additional
serum analysis experiments will be necessary to validate which of
these candidate biomarkers have differential levels in DS versus
normal pregnancies. Furthermore, we cannot predict beforehand
at what gestational age biomarkers are most discriminatory
between normal and DS pregnancies, and as a result, whether
they can be integrated in late first or early second trimester
screening. If this proves not to be the case, the usability of the new
biomarkers in a routine, large-scale population screening program
as applied in The Netherlands will be rather low. These further
experimental validations of the new DS screening biomarkers
identified by our data mining approach will evidently be the
subject of future follow-up studies.
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